Siemens Medical Solutions Medical Device Company Intelligence Report

Summary

Medical Device Company Intelligence Reports from Espicom provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

Siemens AG's medical division, Siemens Medical Solutions, represents over 9% of its parent company's total revenue. Headquartered in Erlangen, Germany, Siemens Medical Solutions is well-known for its medical imaging systems, including X-ray, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), mammography, angiography, ultrasound and molecular imaging (MI) products, as well as related computer-based workstations, healthcare IT systems, oncology care products and audiology products such as hearing aids. Siemens also has a share in Drger Medical, a leader in the market for electromedical systems, including patient monitoring products and electrophysiological measuring systems.

Having established itself as a leader in in vivo diagnostics, the company has recently also made the move into the global in vitro diagnostics market, acquiring Bayer's diagnostic division in January 2007 and Diagnostic Products Corporation (DPC) in July 2006. These companies now operate as the new Siemens Medical Solutions Diagnostics unit, employing over 8,000 people and headquartered in Tarrytown, New York, and Los Angeles, California, USA. Siemens Medical Solutions Diagnostics offers products for clinical chemistry, patient testing, laboratory automation, haematology, molecular diagnostics and gene analysis. Its products are used to diagnose and treat an array of illnesses such as adrenal/pituitary dysfunction, allergy, anaemia, reproductive and thyroid disorders, infectious diseases, kidney ailments, cardiology, oncology, diabetes and virology.

Siemens now claims to hold the second-leading position in the global immunodiagnostics market and is number three in the overall in vitro diagnostics market after Roche and Abbott. DPC and Bayer Diagnostics generated cumulative sales of EUR 1.8 billion in fiscal 2005, ended 31st December. The cost for both acquisitions was EUR 5.7 billion.

In its traditional operations, Siemens Medical Solutions claims to be the global market leader for hearing systems. The company holds a leading or second position in the markets for diagnostic imaging and healthcare IT products, along with GE Healthcare and Philips. It also holds the number three position in the global oncology market after Varian Medical Systems and Elekta.

Siemens is often at the forefront in responding to new trends in the healthcare industry and has built its operations through internal growth, strategic alliances and mergers and acquisitions. The recent addition of its diagnostics business is a good example. In addition, when molecular imaging was a key new area of expansion, the company consolidated its position in this growth market by the acquisition of its former partner, CTI Molecular Imaging, in 2005. CTI was merged with Siemens' existing nuclear medicine activities to form a new Molecular Imaging division.

A more recent example is Siemens' acquisition of Gesellschaft fr Systemforschung und Dienstleistungen im Gesundheitswesen mbH (GSD), a German healthcare IT company. By taking over GSD, Siemens aims to strengthen its position in the healthcare IT sector, especially in Europe. GSD's healthcare IT portfolio includes the i.s.h.med and Ambulatory Care Management (ACM) product lines GSD generated revenue of EUR 25.6 million and employed 168 people in fiscal 2005, ended 31st December.

R&D plays an important role in Siemens Medical Solutions' business and the company maintains R&D centres in Europe, the US and Asia. Currently, the main themes are the development of new technologies such as MI and particle therapy, a cutting-edge technology which many believe will lead to improved radiation therapy for oncology care. The company also focuses on enhancing existing technologies such as CT, ultrasound, mammography, ultrasound and MRI. To complement its internal development, Siemens has many R&D alliances with companies and academic institutions. The company has recently begun US clinical trials with the University of California, Los Angeles, under an FDA investigational new drug application for an imaging biomarker designed to identify Alzheimer's disease before the onset of noticeable symptoms. It has also developed prototype 128-channel MRI system based on its Tim MRI technology in collaboration with Massachusetts General Hospital and signed a licensing agreement for SPECT reconstruction and calibration software developed by the Cleveland Clinic.

Siemens has a strong global presence. The US is the largest single market for its medical device operations, representing around half of sales, followed by Europe and a smaller but significant amount in the Asia-Pacific region. The company's worldwide business is reflected in its regional organisation. The headquarters for the diagnostics, oncology care, healthcare IT, services, ultrasound and MI divisions are located in the US, while the remaining divisions are headquartered in Germany. The company operates manufacturing facilities throughout North America and Europe, as well as in China and India. It also has joint-venture operations in Germany, the US, the UK, China and Japan.

Content